Glaxosmithkline Share News (GSK)

South African pharmaceutical firms say strike causing "very little" disruption

CAPE TOWN, July 29 (Reuters) - An indefinite wage strike launched on Friday by around 8,000 South African pharmaceutical workers has caused "very little" disruption at manufacturing and distribution depots, the Pharmaceutical Employers Association said. Members affiliated to the Chemical, E

South African pharmaceutical workers launch pay strike

CAPE TOWN, July 29 (Reuters) - South African pharmaceutical workers launched an indefinite wage strike on Friday, likely affecting production and distribution depots, a union official said. Clement Chitja said around 8,000 members affiliated to the Chemical, Energy, Paper, Printing, Wood an

BROKER RATINGS SUMMARY: Liberum Downgrades Glencore To Sell

LONDON BRIEFING: Rolls-Royce Is Market's Pick Of Slew Of Interims

UPDATE 4-GlaxoSmithKline invests $360 mln in UK despite Brexit

* Government says decision a clear vote of confidence in UK * Investment at sites making respiratory and biotech drugs * GSK Q2 sales and core earnings beat expectations * Weak pound could boost 2016 earnings by 19 percent (Adds Q2 earnings, further CEO and analyst comment, la

GSK gives earnings guidance a shot in the arm after strong first half

(ShareCast News) - GlaxoSmithKline said strong earnings growth in the second quarter led to expect full year earnings will hit the upper end of targets, with an extra boost coming from the weakness of sterling in the first half of the year. For the full year, GSK said it now expected core earnings p

GSK outlook brightens as Brexit brings currency windfall

By Ben Hirschler LONDON, July 27 (Reuters) - Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union. GSK, whose outgoing chi

GSK chases next biotech asthma drug with $230 mln J&J deal

By Ben Hirschler LONDON, July 27 (Reuters) - GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently

GlaxoSmithKline to invest GBP275m in UK manufacturing sites

(ShareCast News) - Amid growing concerns about how Brexit might affect investment in the UK, pharmaceuticals giant GlaxoSmithKline has announced plans to spend £275m on three of its UK manufacturing sites to boost production and support delivery of its latest respiratory and large molecule biologica

GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing

LONDON, July 27 (Reuters) - GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. (Reporting by Ben Hirschler; Editing by David Holm

Germany plans to extend price brake for drugs under statutory insurance

BERLIN, July 25 (Reuters) - Germany wants to extend a price brake for drugs covered by statutory health insurance for five years beyond 2017, stretching out the measure introduced in 2009, a draft law seen by Reuters shows. The health ministry estimates savings from the extension will amoun

Malaria drug may help in cancer fight, early research finds

LONDON, July 25 (Reuters) - An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early work that has prompted British scientists to start a clinical trial. Researchers reported on Monday that atovaquone boosted oxygen le

UK Earnings, Trading Statements Calendar - Next 7 Days

Your inhaler's watching you: drugmakers race for smart devices

* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung

Novartis in no rush to sell down stake on GSK consumer venture

July 19 (Reuters) - Novartis is happy with the performance of its consumer health joint venture with GlaxoSmithKline, in which the Swiss drugmaker has a minority stake, and is in no rush to exit the collaboration early, its chief executive said. There has been speculation that Novartis migh